Member Info for Thelix

get added today/tomorrow so hopefully we see some movement after that.

Trust me as someone fully loaded here this has confused and irked me a lot. Never ever seen such a lacklustre NASDAQ launch. Hopefully the next few weeks gets some piqued interest

Anyone got anymore buckets? I have cleaned out all of homebase in a 10 mile radius lol. I aptly await today 2pm and also 2pm on target dates for when the ADS's are added to see if this is being controlled at 132 as per the IPO price format. This may genuinely be a flat NASDAQ launch, but I await further data to confirm if this is a damp squib. At least the product is in phase 2 and everything is going as planned - the dilution will be done and voila, we should see an uptrend as new people come on board with the new vision and listing. I am still happy holding here. It has helped up hugely better than I originally thought.

Over 400k share volume which is way over £500,000 and no tick up? Come on thats not right. This was moving 4% odd a few weeks back on 50,000 share volume.

the share dump happening in May is being controlled and keeping the price in the 1.32 region? If this still sees no appreciable rise after those extra shares are in then oh dear.

NASDAQ launches and this is the least it has ever moved. Are we sure the common PI was able to buy ADS's stateside? If not that would explain it. If tomorrow is no different then hmmm. Might have to wait for shares by ii to be put into the roster before we see any movement.

doesn't move at 2pm I will cry lol. I am confident upon the NASDAQ opening (2pm I think) we will see a lot of volume and spiking. But there is always that doubt. Paralysis by Analysis as they say.

this tick up massively starting at ~2pm as it states we will be on the NASDAQ 27th. BOOM. Finally!

Re-read the RNS.... the Company is disappointed to note that, although provisionally agreed by the MHRA in 2016, the FDA has not agreed with the proposed phase III study design based on endoscopic primary endpoints (frequency of erosions and ulcers). The FDA has indicated that in order to support an improved gastro-intestinal ('GI') safety claim, a clinical outcomes study would be required, including measures such as assessment of the incidence of peptic ulcer bleeding and related complications. So OXP KNEW it had to do a trial - it says PROPOSED phase 3. FDA have simply disagreed on what the proposed study should measure. So either way this needed another trial. FDA have simply disagreed with the trials design. Temporary hurt here, not fussed at all - just a potential slip by about 18 months, I can wait that long easily.

OXP revenue continues to grow and they have lowered their cash burn a lot. The placing (at 10p) to which gave them over £20 million in the bank allows the company room to pursue extra costs without riding into more low SP placements. It is frustrating but bottom drawer it. To get to 1p this needs to be valued at 55% of cash held. Personally that wont happen. To rise SP OXP need to 1. Outline a decent revenue capable plan for reduced GI status - which FDA said they could do 2. Outline a trial to which agreed with the FDA will allow a commercial plan of "All GI gone" status 3. Just submit an RNS with some kind of plan. That last RNS has still rubbed me the wrong way how it was written. Instead of stating that the company has taken FDA's terms into account and the company is proactively seeking a strategy to ensure future capability in line with these terms it was just "FDA said no, this is disappointing". Yeah, obviously, care to further state what the company plans are even if they are only forward looking general statements? Markets hate uncertainty and that RNS was written with maximal uncertainty. Dont get me wrong the reassured corporate spiel wouldnt save this from a declining SP but it doubtfully would ave gone to 1.5p which has recovered since. It is nice to see a strong bounce off that price twice. If it slips past 1.5-1.6 then the support line is trashed. 1.5p is 80% cash held so no surprise it bounces quickly off that.

for trial to complete, FDA to look at and agree (or disagree) and sign up to commercial partners. Product on shelves will be longer wait. Unlike other AIM stocks Pharma mcaps are usually very high before any sales. GWP spiked at £2.5 billion making R&D losses of tens of millions year in year out. Its about intellectual property and proven products. FDA approval with a signed partner will spike this massively so no need to wait for commercial (in my opinion). Recruiting for the trial will take the most time, and end line data will need processing, and then submit that to FDA and hope they are satisfied. Trial shouldnt take longer than 12 months, and FDA usually respond within 3. The delay on OTC here is interesting - my guess is they have got an answer back and are now instigating a response to FDA to appeal. Which will be futile, FDA says FDA gets, appeal/justification never works - just do what they want lol.

http://www.nasdaq.com/markets/ipos/company/verona-pharma-plc-999545-83296 Good to see.

1 more trial. Its a setback - not a nail in the coffin, nowhere near. Just means commercialisation has probably slipped by ~18 months. If they do another trial and it gives positive data they will have satisfied FDA and this will go bonkers again.

A blockbuster RNS. Look this is pharma, it takes usually 10 years to commercial and requires dozens of trials. The FDA want a trial with different data. It is a delay, it is disappointing, and annoying, but it doesnt change the fact this has a lot of cash and a product that works and passes trials. The FDA often ask for extra work or further proof of things. Unfortunately it was a trial for OXO which takes longer than many other requests (purely on recruitment). If the RNS stated the FDA were not happy with multiple things and required an entire rework then yeah it would be time to rethink. Buying a share at cash in bank share price or below is a steal. Rx is a difficult market which is why they wanted OTC. If FDA say they can sell it at reduced GI OTC then personally that will generate a lot of revenue. Fork is in the road - let the BoD decide the future. Remember we have the vague gist of the FDA response - they have the full response so our judgement is based on simple points. Hopefully good OTC RNS arrives soon.

GWP went for 100% dilution. Within a month it was 800-900% up. I am a lot happier than a month back now we are starting to properly set out the NASDAQ terms. I am too heavy in here to average down - Even if I bought £10k at half price it would only give me like 20% lower average. Feeling a lot calmer here now. Happy with 100% dilution for listing on the NASDAQ. As the price lifts expect further cash raises but at much lower %'s. The cash being raised here shows they are preparing for immediate phase 3 on the back of phase 2 data coming out later this year.

Amazing how people trade on AIM. FDA asks for a pharma company to perform a clinical trial (of which all previous ones passed) and everyone sells and thinks this has failed. Excellent buying opportunity, mcap now below cash levels, and just needs one positive trial. Shall we devalue all AIM miners because they need one more analysis to get the maiden JORC? Shall we devalue all AIM stocks that need one more prototype batch before manufacture? This went to 1.5p a few months back. People paid in and it went to 3.6p and floated 3p. It has gone back to pre news price as traders have sold at a loss. MM's win again. You dont lose anything until you hit that sell button. I am AMAZED at how people feel as if this now worthless because it has to perform a clinical trial. Its a pharma company. "I did have shares in Tesco but then an independent regulator said they would be monitoring stock checks so thats a no go". So funny. If OXP initiate a trial watch this climb back up. The now considerably long delay in the OTC reply from FDA suggests a different result - they would have put both in at the same time. OTC requires different regulation and expectations. It doesnt help this is an incredibly illiquid stock so a few people sell a total of £8000 and the company loses £1 million mcap due to the SP fall. But it also rises similarly fast. The CEO's wording RNS didnt help either. Instead of saying "This is disappointing but we are cash ready to take forward the FDA's response" it's just "waa waa we didnt get what we want" so everyone sold. I mean - OXP constantly bang on about having enough cash to push this in any circumstance. A circumstance has been thrust upon them and the CEO's buckle. I am still confident here though. Compare this to most AIM shares, this is very safe, just a bump in the road. I can list a few R&D AIM pharmas that are nowhere near 1 trial away from commercial worth more than OXP. Everything is relative. We went from "nearly commercial" to "conditional commercial". Just do the damn trial OXP, unless OTC is allowed at reduced GI too.

AIM is terrible for longterm value investments. Once this is on NASDAQ it will rise. Very happy they are getting on with it now.

Time to be filtered. You are getting emotional and exaggerating my points. The feedback was 1 trial needed. Not bad for pharma to need 1 more trial for go ahead. Bye.

Are you purposefully being dense and twisting my words or do you genuinely not understand? OXP fulfilled many clinical trials over the past 3-4 years. These trials were setup to identify the formulations ability to reduce/remove GI irritation. These trials were presented to a regulating body (MHRA) which was accepted. The trials used the most recently recognised measuring system of Lanza scores. Given the trials were performed as per requirement, with the most up to date techniques, and accepted by a world leading regulating body, OXP felt it was confident the FDA would also accept the data. The FDA want a trial that gathers MORE data. So when you say "OXP didnt know it needed a trial and thats normal is it?" you are severely exaggerating the point I am making. Let me also tell you that through some research other GI meds currently approved didnt have to get bleed rates like OXP is being asked of. There isnt a magical list of things which the FDA explicitly says will guarantee you an IND. All medicine is different and many need bespoke data. This is WHY these types of FDA meetings are held so you know what to do next. OXP has cash, ii backing, and ONE trial to perform to meet FDA expectations. There are many pharmas on AIM worth multiples of OXP that need 5+ trials before NDA and commercialisation. Also the trials are more than likely going to pass because it isnt groundbreaking unknown medicine where you could get bad trial data. Its better formulated medicine. Again, the FDA asking for BETTER DATA, than is currently held, is not new, and is common. Stop exaggerating the point I made. We still have OTC, and if FDA offer them an IND to commercialisation for reduced GI irritation for OTC they should take it as it will be direct revenue.

The MHRA accepted the data. The FDA did not. Please explain EXPLICITLY how the BoD messed up? I am telling you now as someone in this industry that the FDA being difficult and asking for more than other regulators is normal. People are getting angry because a pharma company has to do ONE more trial. Grow up - thats part and parcel of investing in pharma. Its a bump in the road. At no point did FDA reject this otherwise they would have stated to OXP this is a no go product end of discussion and this would be delisted. Considering this is OXP's first formal FDA meeting they came away well. Just get on with the trial the FDA want and go to market. Or OTC as reduced GI hopefully.